President & CEO, IDD | Executive Director, VRC Medical Services

How Expanded Access Programs Get Medicines to Patients Outside a Trial

Table of Contents

Pharmacist in a white coat completing paperwork at a desk beside a laptop

Every so often a request lands that no protocol anticipated. A patient is seriously ill, the approved options are exhausted, there is an investigational medicinal product in development that might help, and they cannot join the trial. An expanded access program is the regulatory route that exists for exactly this situation, and much of the difficulty in running one is not regulatory at all. It is supply.

I have spent my career on the infrastructure side of getting medicines where they need to be, and expanded access is where that infrastructure gets tested hardest. This guide explains what these programs are, the categories the FDA recognises, who qualifies, how charging works, and the operational realities that decide whether a program is deliverable.

What an Expanded Access Program Is

An expanded access program is a pathway that allows patients with a serious or immediately life-threatening condition to receive an investigational drug outside a clinical trial. It is sometimes called compassionate use. The regulations sit in 21 CFR Part 312, Subpart I.

The purpose is treatment, not research. That distinction shapes everything downstream. A clinical trial is designed to generate evidence, so it has a protocol, endpoints, inclusion criteria and a statistical plan. Expanded access exists because a specific patient needs a specific medicine now. Data is still collected and safety is still reported, but the reason the patient is receiving the drug is the patient.

The mechanism is not new. The FDA has operated access pathways of this kind for more than three decades, and the modern framework formalised what had been happening case by case.

The Three Categories the FDA Recognises

The regulations organise expanded access by the size of the population being treated. The category determines how much structure the program needs.

Individual patients, including emergency use

The single-patient route, and the most common. A treating physician requests the drug for one named patient. Where the situation is an emergency, treatment can begin before the written submission is complete, with the paperwork following. This is the route most physicians encounter, and it can move quickly when the company agrees.

Intermediate-size patient populations

Used when a group of patients needs access but a full treatment program is not warranted. This sits between the single-patient route and widespread use, and it usually appears when a drug is in development for a rare condition and requests are arriving faster than a case-by-case process can absorb.

Widespread treatment use

The largest category, sometimes called a treatment IND or treatment protocol. It is used for a serious or life-threatening disease when a drug is already in late-stage development. This route carries the most structure and the most reporting.

Who Qualifies

The criteria are consistent across the categories. The patient must have a serious or immediately life-threatening disease or condition, and there must be no comparable or satisfactory alternative therapy available.

Beyond the patient’s situation, the practical conditions are these. The company developing the drug has to agree to provide it, which is a genuine decision on their part and not a formality. Informed consent has to be obtained under the requirements in 21 CFR Part 50. An institutional review board has to review the treatment under 21 CFR Part 56. And safety reporting obligations under 21 CFR 312.32 and 312.33 apply.

For single-patient use, the sponsor must give the FDA a written summary of the results after treatment ends, including any adverse effects. Access does not mean the obligations disappear.

Expanded Access and Right to Try Are Not the Same Thing

These get conflated constantly, and the difference is worth stating plainly.

Under Right to Try, the FDA does not review or approve requests. Its role is limited to receiving and posting certain information. The eligibility conditions are specific: the patient must have a life-threatening disease, must have exhausted approved treatment options, and must be unable to participate in a clinical trial. A physician in good standing certifies the case, and written informed consent is obtained through that physician. The drug must have completed Phase 1, must remain unapproved, must be under an active IND or investigation, must not be on clinical hold, and must be in active development. Manufacturers file annual reports by 31 March covering the drug name, IND numbers, doses supplied, patient numbers, the condition treated and serious adverse events.

The practical difference is oversight. Expanded access runs through the FDA and an institutional review board. Right to Try removes the agency from the decision. Neither pathway obliges a company to supply anything, which is the point most patients and families are surprised by, and the point worth being honest about early in any conversation.

Named Patient Programs and the Vocabulary Elsewhere

Outside the United States the same idea travels under different names. Named patient programs, compassionate use programmes, and early access schemes describe broadly similar arrangements, with the details set by each national regulator.

For anyone running a program across several countries, the vocabulary problem is not cosmetic. A named patient program in one market may require an import licence, a local representative and pharmacovigilance reporting into a national system that has nothing to do with the FDA. Assuming one framework covers the world is the single most expensive assumption in this area.

Can a Company Charge for the Drug?

Sometimes, and only with permission. Under 21 CFR 312.8, a sponsor needs prior written authorisation from the FDA to charge for an investigational drug at all.

What may be recovered is limited to direct costs. That means manufacturing, acquisition, shipping and handling costs directly attributed to providing the drug. For expanded access specifically, the sponsor may also recover monitoring costs, the costs of complying with IND reporting, and associated administrative costs. Cost calculations must be verified by an independent certified public accountant.

The sponsor also has to give reasonable assurance that charging will not interfere with developing the drug for marketing approval. Authorisation for expanded access charging lasts one year and applies only to the patient population it was granted for. In practice most companies supply at no charge, because the administrative burden of the alternative outweighs the recovery.

The Supply Side of an Expanded Access Program

This is the part that gets underestimated, and it is where I have watched well-intentioned programs stall.

Trial supply is forecastable. You know the sites, the countries, the visit schedule and the enrolment target, even if the target is optimistic. An expanded access program has none of that. Requests arrive unpredictably, from countries the study never opened, for patients whose treatment duration is unknown because they will continue while they benefit.

That creates three problems at once. Demand cannot be forecast in the usual way, so safety stock has to be held against a distribution nobody can model. Supply has to reach single patients in territories with no study infrastructure, which means import permits, an importer of record and a local pharmacy prepared to receive investigational product. And that supply must not compete with the pivotal trial, because a program that starves the study delays approval for everyone.

The third point is the one that decides most programs. Every unit given to an expanded access patient is a unit not available to a trial patient. When manufacturing capacity is constrained, and for a novel biologic it usually is, this is a real allocation decision with real consequences either way. It should be made deliberately, with a written policy, rather than request by request under pressure.

Why Companies Say No

Refusals are rarely about indifference, and understanding the reasons helps everyone have a more useful conversation.

Supply constraint is the most common. Early manufacturing runs are small, and a company genuinely may not have product to spare without compromising the trial. Safety data is the second: with limited human exposure, the risk profile in a sicker population outside trial monitoring may be unknown in ways that matter. Third is the concern that a serious adverse event in an expanded access patient, who is by definition very unwell, may complicate the development program even where the drug was not the cause. Fourth is simple capacity, since running a program well requires people and systems a small company may not have.

None of these are comfortable answers to give a family. But a company that has thought them through and written a clear policy can respond quickly and consistently. One that has not will be slow, and the delay itself becomes the harm. Building that policy before the first request arrives is the single most useful thing a development-stage company can do here, and it is of a piece with the argument I have made about reliable drug access underpinning clinical research.

Building a Program That Holds Up

The programs that work share a few features. A published policy, so physicians know whether to ask before they ask. A single named route for requests, rather than enquiries arriving through five channels. A defined decision timeline, because a slow yes is often worse than a fast no. A supply plan that reserves product explicitly rather than borrowing from trial stock. And a country-by-country regulatory map built before requests arrive, since import requirements take longer to satisfy than anything else in the chain.

The same discipline that makes clinical trial supply chain management work applies here, with less predictability and higher stakes. If anything, an expanded access program demands more planning than a trial does, because it cannot rely on a protocol to tell it what happens next.

Frequently Asked Questions

What is an expanded access program?

It is a regulatory pathway allowing patients with a serious or immediately life-threatening condition to receive an investigational drug outside a clinical trial, where no comparable or satisfactory alternative therapy exists. It is also called compassionate use.

What are the three FDA categories of expanded access?

Expanded access for individual patients, including for emergency use; expanded access for intermediate-size patient groups; and expanded access for widespread treatment use.

Does a company have to provide a drug if asked?

No. The company’s agreement to supply is a required condition, and it is a decision the company makes. Neither expanded access nor Right to Try obliges a manufacturer to provide an investigational drug.

Can a patient be charged for an investigational drug?

Only with prior written authorisation from the FDA under 21 CFR 312.8, and only for direct costs such as manufacturing, acquisition, shipping and handling. Expanded access programs may also recover monitoring, IND reporting and administrative costs, verified by an independent accountant.

How is Right to Try different from expanded access?

The FDA does not review or approve Right to Try requests; its role is limited to receiving and posting certain information. Expanded access requests go through the FDA and an institutional review board. Right to Try also requires the drug to have completed Phase 1 and to remain in active development.

What is a named patient program?

It is the term used in many countries outside the United States for arrangements similar to single-patient expanded access. The requirements are set nationally and often include import licences and local pharmacovigilance reporting.

The Bottom Line

An expanded access program is a regulatory pathway with a logistics problem attached, and the logistics are usually what determines whether it works. The rules are knowable: three categories, clear eligibility criteria, strict limits on charging. What is harder is holding stock against demand nobody can forecast, reaching single patients in countries with no study infrastructure, and doing it without taking product from the trial that will bring the drug to everyone else. Companies that decide their position in advance can answer quickly. That speed is itself a form of care. You can read more about my work in this area or reach out directly.

This article is for general educational purposes and reflects industry practice in clinical research. It is not medical, regulatory, or legal advice.